Lala Forrest1, Caroline Sedmak1, Shanaz Sikder1, Shivraj Grewal1, S Mitchell Harman2, Marc R Blackman3,4,5, Ranganath Muniyappa6. 1. Clinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 2. Endocrinology Section, Department of Medicine, Phoenix VA Health Care System, Phoenix, AZ, USA. 3. Research Service, Veterans Affairs Medical Center, Washington, DC, USA. 4. Department of Medicine, Georgetown University School of Medicine, Washington, DC, 20007, USA. 5. Department of Medicine, George Washington University School of Medicine, Washington, DC, 20052, USA. 6. Clinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. muniyapr@mail.nih.gov.
Abstract
PURPOSE:Growth hormone (GH) replacement decreases insulin sensitivity in healthy individuals. However, the effects of GH on organ-specific insulin sensitivity and glucose effectiveness are not well characterized. The purpose of this study was to evaluate the effects of GH administration for 26 weeks on muscle and hepatic insulin sensitivity and glucose effectiveness in healthy older individuals. METHODS: This report is from a 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling older women and men. We compared surrogate indices of insulin sensitivity [quantitative insulin-sensitivity check index (QUICKI), muscle insulin sensitivity index (MISI), hepatic insulin resistance index (HIRI)] and glucose effectiveness [oral glucose effectiveness index (oGE)] derived from oral glucose tolerance tests (OGTTs) in subjects before and after 26 weeks of administration of GH (n = 17) or placebo (n = 15) as an exploratory outcome. RESULTS:GH administration for 26 weeks significantly increased fasting insulin concentrations and HIRI but did not significantly change MISI or oGE compared to placebo. CONCLUSIONS:GH administration for 26 weeks in healthy older subjects impairs insulin sensitivity in the liver but not skeletal muscle and does not alter glucose effectiveness.
RCT Entities:
PURPOSE:Growth hormone (GH) replacement decreases insulin sensitivity in healthy individuals. However, the effects of GH on organ-specific insulin sensitivity and glucose effectiveness are not well characterized. The purpose of this study was to evaluate the effects of GH administration for 26 weeks on muscle and hepatic insulin sensitivity and glucose effectiveness in healthy older individuals. METHODS: This report is from a 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling older women and men. We compared surrogate indices of insulin sensitivity [quantitative insulin-sensitivity check index (QUICKI), muscle insulin sensitivity index (MISI), hepatic insulin resistance index (HIRI)] and glucose effectiveness [oral glucose effectiveness index (oGE)] derived from oral glucose tolerance tests (OGTTs) in subjects before and after 26 weeks of administration of GH (n = 17) or placebo (n = 15) as an exploratory outcome. RESULTS:GH administration for 26 weeks significantly increased fasting insulin concentrations and HIRI but did not significantly change MISI or oGE compared to placebo. CONCLUSIONS:GH administration for 26 weeks in healthy older subjects impairs insulin sensitivity in the liver but not skeletal muscle and does not alter glucose effectiveness.
Authors: A M Rosenfalck; S Maghsoudi; S Fisker; J O Jørgensen; J S Christiansen; J Hilsted; A A Vølund; S Madsbad Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: Thomas Münzer; Clifford J Rosen; S Mitchell Harman; Katherine M Pabst; Carol St Clair; John D Sorkin; Marc R Blackman Journal: Am J Physiol Endocrinol Metab Date: 2006-01-03 Impact factor: 4.310
Authors: S Kasayama; M Otsuki; M Takagi; H Saito; S Sumitani; H Kouhara; M Koga; Y Saitoh; T Ohnishi; N Arita Journal: Clin Endocrinol (Oxf) Date: 2000-05 Impact factor: 3.478
Authors: Niels Jessen; Christian B Djurhuus; Jens O L Jørgensen; Lasse S Jensen; Niels Møller; Sten Lund; Ole Schmitz Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Shauna D O'Donovan; Michael Lenz; Gijs H Goossens; Carla J H van der Kallen; Simone J M P Eussen; Coen D A Stehouwer; Marleen M van Greevenbroek; Miranda T Schram; Simone J Sep; Ralf L M Peeters; Ellen E Blaak; Natal A W van Riel; Theo M C M de Kok; Ilja C W Arts Journal: Sci Rep Date: 2019-06-28 Impact factor: 4.379
Authors: Nobuhiko Nagano; Chizuka Kaneko; Shoko Ohashi; Megumi Seya; Itsuro Takigawa; Ken Masunaga; Ichiro Morioka Journal: Int J Environ Res Public Health Date: 2022-07-13 Impact factor: 4.614